Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace
EX-99.1
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
Pfizer Announces Agreement with Puma Biotechnology and Lyrica Success - Clinical Professionals
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)
Nerlynx: Package Insert - Drugs.com
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Biotechnology
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
FLASCO / FDA Clears Puma Biotechnology's Nerlynx for Extended Adjuvant Treatment of HER2-positive Early-Stage Breast Cancer
Why Shares in Puma Biotechnology Inc. Are Plunging | The Motley Fool
Puma Biotechnology
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology Neratinib Product Launch - YouTube
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Puma's Nerlynx unleashed to fight HER2+ breast cancer with 'best case' label | Fierce Pharma
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Puma Biotech Gets Favorable FDA Vote On Neratinib - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
